-
| ISIN | US45250K1079 |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Beta | nan |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | 36 |
| PE Ratio | None |
| Market Cap | 1B |
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California. As of January 11, 2023, Imago BioSciences, Inc. operates as a subsidiary of Merck Sharp & Dohme Corp..
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IMGO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024